RAIN — Rain Oncology Share News
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million
Brief: Rain Oncology Confirms Receipt Of Unsolicited Proposal From Concentra Biosciences
Rain Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Rain Therapeutics Inc Q2 basic EPS USD -0.61
Rain Oncology Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Rain Oncology Inc Sees About $2.4 Million To $2.6 Million In Charges In Connection With Restructuring Plan
U.S. RESEARCH ROUNDUP-Apple, Estee Lauder Companies, SentinelOne
Rain Oncology falls on plans to suspend enrollment for lead drug mid-stage study
Brief: Rain Oncology Provides Company Update And Outlines Strategic Priorities Of Milademetan Clinical Programs
U.S. RESEARCH ROUNDUP-Cleveland-Cliffs, Graftech International, Steel Dynamics
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
Rain Oncology falls as lead asset fails late-stage study
Brief: Rain Oncology Announces Topline Results From Phase 3 MANTRA Trial Of Milademetan
Rain Oncology Inc reports results for the quarter ended in March - Earnings Summary
Brief: Rain Oncology Reports First Quarter 2023 Financial Results And Highlights Recent Progress